摘要
目的比较以硼替佐米为基础的方案治疗多发性骨髓瘤静脉给药和皮下给药2种方式对临床疗效和安全性的影响,探索更适宜的给药方式。方法回顾性分析45例多发性骨髓瘤患者的临床资料,分别采用皮下和静脉注射硼替佐米(1.3 mg/m^2),第1、4、8、11天。汇总2种给药方式的疗效和不良反应。同时分析影响患者预后的影响因素。结果2种给药方式患者总体生存率及无进展生存期之间的差异无统计学意义;2种给药方式患者的临床疗效差异无统计学意义。2种给药方式患者周围神经病变的发生率对比差异有统计学意义(P=0.030,P<0.05),余不良反应发生率2种给药方式患者差异无统计学意义。结论硼替佐米2种给药途径的临床疗效相当,皮下应用可能比静脉应用不良反应发生率低。
Objective Treatment of multiple myeloma with bortezomib-based regimens has made significant progress in the prognosis of patients.In the past,the use of intravenous administration has been limited to a certain extent,but its side effects have limited its application.Methods In this study,45 patients with multiple myeloma were analyzed retrospectively.Bortezomib was injected subcutaneously(SC group)or intravenously(IV group)at the dose of 1.3 mg/m 2,on D1,D4,D8,and D11.The efficacy and adverse reactions of the two ways of administration were observed.At the same time,the influencing factors of prognosis were analyzed.Results There was no significant difference in OS(P=0.163,P>0.05)and PFS(P=0.688,P>0.05)between the two groups.There was no significant difference in clinical efficacy between the two groups(P=0.760,P>0.05).The incidence of peripheral neuropathy adverse reactions between the two groups was statistically significant(P=0.030,P<0.05).No statistically significant difference between the two groups was observed regarding other adverse reactions(P>0.05).Conclusions The clinical efficacy of two routes of administration of bortezomib is similar,but the incidence of adverse reactions of subcutaneous bortezomib is lower than that of intravenous bortezomib.
作者
何月茹
李振宇
许婷
徐开林
HE Yueru;LI Zhenyu;XU Ting;XU Kailin(Department of Hematology,the Affiliated Hospital of Xuzhou Medical University,Xuzhou,Jiangsu 221002,China)
出处
《徐州医科大学学报》
CAS
2020年第3期196-198,共3页
Journal of Xuzhou Medical University
关键词
多发性骨髓瘤
硼替佐米
皮下注射
静脉注射
multiple myeloma
bortezomib
subcutaneous injection
intravenous injection
